{"analyses":[{"ciLowerLimit":"-0.09","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.001","dispersionType":"STANDARD_ERROR_OF_MEAN","dispersionValue":"0.023","groupIds":["OG000","OG001"],"nonInferiorityType":"OTHER","pValue":"0.05","paramType":"Slope","paramValue":"-0.045","statisticalComment":"The treatment effect was determined by testing the significance of the group by time interaction in GEE using a one degree-of-freedom (df) test.","statisticalMethod":"Generalized Estimating Equation (GEE)"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.043","value":"03.2765"},{"groupId":"OG001","spread":"0.0459","value":"3.2396"}]}],"title":"BL"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.0382","value":"3.2901"},{"groupId":"OG001","spread":"0.0442","value":"3.3023"}]}],"title":"6m"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.043","value":"3.262"},{"groupId":"OG001","spread":"0.0571","value":"3.2964"}]}],"title":"12m"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.0436","value":"3.32"},{"groupId":"OG001","spread":"0.0579","value":"3.2798"}]}],"title":"18m"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.0435","value":"3.2441"},{"groupId":"OG001","spread":"0.0607","value":"3.286"}]}],"title":"24m"}],"denoms":[{"counts":[{"groupId":"OG000","value":"75"},{"groupId":"OG001","value":"76"}],"units":"Participants"}],"description":"Thickness of cardiac muscle (in cm) of the left ventricle at the end of systole. The mean is reported by arm at each timepoint with corresponding standard errors.","dispersionType":"Standard Error","groups":[{"description":"Patients received Carvedilol PO delivered at 6.25 mg twice daily (for a total dose of 12.5 mg per day) for 24 months.","id":"OG000","title":"Arm I (Carvedilol)"},{"description":"Patients received Placebo PO delivered at 6.25 mg twice daily (for a total dose of 12.5 mg per day) for 24 months.","id":"OG001","title":"Arm II (Placebo)"}],"paramType":"MEAN","populationDescription":"We excluded 31 participants who did not have a second time point assessment of echocardiography, resulting in 151 analyzable participants.","reportingStatus":"POSTED","timeFrame":"Baseline before treatment, 6 months, 12 months, 18 months, 24 months after treatment initiation","title":"Average Left Ventricular End-systolic Dimension","type":"SECONDARY","unitOfMeasure":"centimeter"}